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Background: Existing evidence suggests that there is often limited understanding among participants in clinical
trials about the informed consent process, resulting in their providing consent without really understanding the
purpose of the study, specific procedures, and their rights. The objective of the study was to determine the
subjects’ understanding of research, perceptions of voluntariness and motivations for participation in a malaria
clinical trial.
Methods: In this study semi-structured interviews of adult clinical trial participants with uncomplicated falciparum
malaria were conducted in Ramu Upazila Health Complex, in Bangladesh.
Results: Of 16 participants, the vast majority (81%) were illiterate. All subjects had a ‘therapeutic misconception’
i.e. the trial was perceived to be conducted primarily for the benefit of individual patients when in fact the main
objective was to provide information to inform public health policy. From the patients’ perspective, getting well
from their illness was their major concern. Poor actual understanding of trial specific procedures was reported
despite participants’ satisfaction with treatment and nursing care.
Conclusion: There is frequently a degree of overlap between research and provision of clinical care in malaria
research studies. Patients may be motivated to participate to research without a good understanding of the
principal objectives of the study despite a lengthy consent process. The findings suggest that use of a standard
consent form following the current ICH-GCP guidelines does not result in achieving fully informed consent and
the process should be revised, simplified and adapted to individual trial settings.
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Regulatory authorities and ethical guidelines emphasize
the need for research subjects to understand the informed
consent process [1-4]. Ensuring that appropriate infor-
mation is disclosed to potential research participants in an
understandable manner in order to empower them to
make a voluntary decision is one of the key ethical require-
ments in biomedical research [4].
The ICH guideline on Good Clinical Practice lists
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unless otherwise stated.information sheet and consent form [5]. Achieving genu-
ine informed consent is becoming more difficult as patient
information sheets get longer and clinical trials become
increasingly complicated with the continued expansion of
research into new areas such as molecular biology and
genetics. The vocabulary to describe all these new tech-
niques does not exist in all languages. Despite this, ethics
committees put a lot of emphasis on obtaining informed
consent for genetic testing or the storage of samples for
future research.
It has been recognized widely by ethicists and medical
researchers that trial participants may not completely
understand the information they are being provided with,
and may have very little idea of what they are actually con-
senting to when they agree to be involved in biomedical. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and not only a problem restricted to less developed coun-
tries [6-10]. However, the decision to participate in re-
search in resource constrained settings is more likely to be
swayed by other factors since, in general, potential partici-
pants are more likely to come from vulnerable groups in
the community [6]. For example, they are more likely to
have lower educational status, more linguistic barriers,
lower socio-economic conditions, and limited experience
of health care and research which will impact on their
understanding and perception of research and eventually
the entire informed consent process. Understanding of
consent remains a relatively under-researched area in
developing country contexts.
Context and rationale
A study site was established in Ramu Upazila Health
Complex (UHC), Cox’s Bazar, Bangladesh, as part of a
multicentre clinical trial by the “Tracking resistance to
Artemisinin Collaboration – TRAC” (Clinical trial regis-
tration number NCT01350856) in patients with uncom-
plicated falciparum malaria. The sub-district hospital
provides primary health care services for 167,480 inhabi-
tants in Ramu, who are predominantly illiterate (average
literacy rate 34%) and usually make a living by farming,
tree plantation and physical labour (1991 Bangladesh
census). In 2011, malaria accounted for 6% of inpatient
hospital admissions in Ramu UHC (Ministry of Health
and Family Welfare Health Bulletin 2012). Malaria, one
of the common causes of febrile illness, is often mani-
fested by headache, malaise, muscle-ache, nausea, vomit-
ing, anorexia, fever with chills and rigors, or in its severe
form by coma and convulsions. The TRAC study invol-
ved an inpatient hospital stay, which would not have
been otherwise indicated for the routine medical care
for the treatment of uncomplicated malaria. Patients
were hospitalized in order to monitor the decrease in
parasitaemia precisely as a marker of artemisinin suscep-
tibility which was the main end-point of the study. The
study also involved frequent blood sampling from sub-
jects and storage of samples for future research such as
measurement of drug concentrations, and in vitro, mo-
lecular and parasite genetic assays. The complex nature
of the trial in the context of a resource-poor setting
prompted the researchers to design a pilot sub-study on
the informed consent process.
Objectives
The objective of the current study was to assess the par-
ticipants’ understanding of research, their perception of
voluntariness and to determine factors influencing their
decision making process in regards to participation in a
clinical trial in Bangladesh. The study also aimed to get
a better understanding of participants’ concerns relatedto specific procedures (e.g. frequent blood sampling, long
hospital admission) and future use of samples, as well as
identifying the barriers to achieving study comprehension
in a developing country context.
Methods
Patients and study procedures
In this qualitative study, adult (>18 years) patients with
malaria that consented to the TRAC clinical trial in
Ramu Upazila Health Complex, Cox’s Bazar, Bangladesh
were interviewed between July and October 2012. The
clinical trial was already underway when approval for
this study was obtained and 13 patients out of a total of
56 had been recruited. Potential participants for this
sub-study were selected sequentially by purposive sam-
pling from the TRAC study ward commencing with the
fourteenth study subject. Two of the authors (FA and DD)
approached individuals and briefly invited them to take
part in an in-depth interview. If individuals expressed
interest, they were accompanied to a private room where
they received further information about the study. If they
agreed to be interviewed, then verbal consent in the local
language (Bangla) was obtained and documented on the
audiotape. It was made clear that participation in this sub-
study was solely voluntary and refusing consent for this
would not jeopardize clinical care and treatment in the
main TRAC trial. The interview and entire conversation
between the respondent and the interviewer was recorded
using a digital tape recorder for the purpose of future
translation and transcription. The information collected
from interviewees was anonymous and confidentiality was
strictly maintained. Ethical approval was obtained from
the Oxford Tropical Medicine Ethics Committee, and
Bangladesh Medical Research Council.
Data collection tools
A semi-structured interview guide was designed to cap-
ture patients’ perceptions and understanding of research,
the informed consent process and TRAC trial specific
procedures (see Additional file 1). The questions were
grouped in categories according to the study objectives.
The interviews were conducted by a researcher during
hospital admission (on the second or third day after enrol-
ment) once the participants’ acute symptoms of malaria
had resolved. The interviewers had been trained on the
purpose of the study, data collection tools and techniques.
The interview was recorded using a digital tape recorder if
permission was given by the respondent.
Informed consent process
Three study nurses were responsible for obtaining infor-
med consent to participate in the TRAC clinical trial.
Before the trial, in addition to the TRAC protocol proce-
dures, the research team went through a one-day Good









Cannot read or write 2 (12)
Cannot read but can write name 11 (69)
Primary schooling 3 (19)
Occupation
Farmer 3 (19)
Day labourer 9 (56)
Govt. or private employee 2 (12)
Household work 2 (12)
Language
Bangla only 2 (12)
Both Chittagonian and Bangla 14 (88)
Monthly income (BDT)
< = 5,000 7 (44)
> 5,000 9 (56)
Abbreviation: BDT, Bangladeshi Taka.
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on training on how to obtain written informed consent
from study subjects. This included explanation of the
utility and obligations of information provision for poten-
tial research participants according to international codes
of ethics.
Statistical analysis
Adult patients enrolled in TRAC trial at Ramu UHC
were selected sequentially for in-depth interviews using
a semi-structured interview guide. The conversation be-
tween a subject and an interviewer was recorded. Literatim
transcripts of the interviews were translated into English.
All transcripts were reviewed and major themes were
highlighted and discussed by the researchers. An arbitrary
sample size of 16 was selected for this exploratory study
which was considered to provide sufficient data to explore
the study questions.
Results
A total of 16 of the 56 patients enrolled in the clinical
trial were interviewed (29%). Three adult male patients
from the same villages as other participants recruited
and completed follow up in the clinical trial but refused
to participate in this qualitative sub-study. No reason
was given for refusal. The average duration of the inter-
view was about 30 minutes. The respondents were pre-
dominantly male (88%) from Bangali ethnic background
(100%) and the median age was 27 years (range, 18–51).
This reflected the age and gender distribution of the
patient recruitment to the clinical trial, a consequence of
the fact that in Asia malaria is mainly an occupational
disease of young men. More than three quarters of the
interviewees (13/16) were illiterate (i.e. could not read or
write or could not read but were able to write or sign
their name). All participants lived in villages and three
fourths worked either as farmers or day labourers. The
average monthly income of this subject cohort was
approximately 6500 Bangladeshi Taka (BDT) ranging
from 3000–12500 BDT (1 USD = 80 BDT). In regards to
languages spoken, the majority of participants (88%)
could speak Chittagonian (the local dialect) in addition
to Bangla (the official language of Bangladeshi people).
The characteristics of the participants are given in
Table 1.
Perceptions of research
None of the sub-study subjects had previous experience
of participation in clinical research. The vast majority
had limited experience with routine medical care pro-
vided in hospitals. Half of the patients had never had
malaria before. However, their responses demonstrated a
reasonably good understanding of malaria. This general
malaria awareness might be explained by the activities ofthe National Malaria Control Programme (NMCP), in
collaboration with local partners (such as Mukti, a NGO
in Ramu) providing diagnostics, treatment services and
health education at village level in malaria endemic areas
in Bangladesh.
‘I went to Alikadam, Bandarban hill and stayed there
for 24 days to collect wood. I took bed net with me but
I was bitten by mosquitoes during day time and also
at night as it was rainy season. Nothing happened
there, but upon arrival at home, I started feeling sick
after 2 days along with fever, chills & rigor, muscle-
ache and came to Ramu hospital on the next day. ….
The doctor sent me for blood testing. Then I was told
that I had malaria’.
In contrast, the subjects showed relatively poor actual
understanding of the research activities. The TRAC trial
involved specific procedures, i.e., repeated blood sampling
and inpatient hospital stays which are not practised in
routine hospital management of uncomplicated malaria.
None of the subjects interviewed mentioned the purposes
of storage of samples for future drug measurement and
genetic studies. Regarding blood sampling, the perceptions
were mainly:
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about the amount and frequency of blood taken.
I said about a spoonful each time. He asked me to
continue and assured that this should be fine, no
problem. Prompted by the interviewer - OK, so your
friend reassured you. But why did they take blood
samples from you? The respondent mentioned
“to test my blood, to see the germs and eventually,
to make me well”.
Furthermore, three out of 16 subjects justified their
inpatient hospital admission by having severe malaria
which was a wrong perception. Others mentioned the
purpose of hospital admission was to ensure cure from
the illness. In terms of anti-malarial treatment, the vast
majority had a clear idea of the duration of treatment.
Almost all respondents thought they understood the
reason they were asked to participate in the research.
However, none of them had actual and thorough under-
standing of the objectives of the trial. They considered the
clinical study aimed at providing good treatment and indi-
vidual cure from the illness as quoted below:
‘I understand that I will get treatment and I will
recover, by the grace of Allah. They told me many
things but I didn’t understand everything’.
Voluntariness
During the informed consent process, the study nurses
who were responsible for obtaining consent read the
patient information form (PIF) to all participants and
also provided them with a copy of the PIF (see Additional
file 2). All participants made a voluntary decision to par-
ticipate in the TRAC trial. However, many admitted that
they could not remember or understand everything that
was explained to them because of their malaria symptoms
during the informed consent process. In addition, most
subjects (N = 15) were not aware of their right to quit the
research anytime if they wished to do so. They rather
wanted to continue after being enrolled as they had com-
mitted to this at the beginning. They also felt obliged to
adhere to the study until the end so that they would get
complete recovery from their malaria. One participant
stated:
‘I don’t feel like quitting the study. Why should I? If I
wanted to leave the study, I would say that. They told
me at the beginning that I could only take part if I
wanted to stay for 7 days. I agreed. I will be staying
here till the end’.
There were mixed responses (8/16 subjects thoughts
of not having treatment) related to perceptions of the
availability of treatment in hospital if anyone declined toparticipate in the trial or withdrew consent after being
enrolled.
‘It depends on the doctors. If I said I was afraid to
participate, they might not treat me’.
‘I would get treatment from hospital. Everyone is
getting treatment here’.
Factors influencing participation
The major factors influencing subjects’ decisions to par-
ticipate in the research were availability of free medical
treatment, access to good quality treatment and nursing
care and financial support to compensate loss of work
during the inpatient hospital admission. Some responses
are listed below:
‘You have given me good care, I will tell others about
this. I will tell them about the availability of good
treatment here and the benefits I have received’.
‘If I wanted to get treatment from outside, I had to buy
medicine. I wouldn’t get good medicine. There could be
chance of getting malaria again. I think I have got
good medicine here for many times’.
‘If I get treatment from outside, I won’t get well. Here
in the hospital, treatment is free. I had to spend a lot
of money to buy medicine for having treatment
outside. I am poor, that’s why I have come here.’
The trial participants expressed high satisfaction with
both the treatment received and the nursing care. They
pointed out the availability of good quality treatment, free
medication, and cure from the illness as major advantages
of taking part in this trial. Most patients didn’t mention
any inconveniences of being a research participant. Many
thought blood samples were collected several times to
investigate their disease progress, appreciated inpatient
hospital admission and good nursing care. To the respon-
dents, the most important aspect of their research partici-
pation was ‘to get well from malaria’.
‘They can take whatever they want if I get well. If they
take my flesh, I have no problem…. The interviewer
asked whether there was any problem with long
hospital stay. The subject said “no problem at all”.’
Concept of being informed
Almost all subjects thought blood samples were taken
for further investigations at home and abroad for the
betterment of the individual patients. They were not
interested in further details of the type of research (such
as pharmacokinetic or genetic studies) the samples might
be used for. No one found it important for the study team
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abroad for future research; instead they stated that this
could be solely the researcher’s decision. Similarly, the
respondents did not have a clear idea about further use of
information collected through this clinical trial. The sub-
jects were grateful to the study team due to having good
treatment and nursing care, and none felt like asking any
questions about research procedures.
‘I do not need to understand well. I am cured from my
disease and I am happy for this’.
Discussion
Informed consent is pivotal in protecting participants’
rights in human research. However, it is a challenge to
ensure subjects are adequately informed and actually
understand research goals and methods and able to
make a voluntary decision in taking part or declining
participation. Clinical trial guidelines do not explicitly
define actual understanding of informed consent. Thus
documentation of comprehension is not required. This
exploratory study highlighted a ‘therapeutic misconcep-
tion’ in which the participating patients viewed research
activities as treatments aimed at managing their medical
condition. From the patients’ perspectives, getting well
from their illness was the major concern and participat-
ing in the trial was considered as the best treatment op-
tion. These particular subjects had no previous exposure
to research and very little experience of institutional
health care. The issue of research-treatment distinction
has long been debated in bioethics [11-13]. Some argue
that clinical research (whose goal is to generate gene-
ralizable knowledge) and medical care (focused on per-
sonalized care) should have clear-cut boundaries and
are concerned about the dangers of mixing clinical re-
search with treatment [14,15]. The potential for availabil-
ity of free treatment and greater access to good quality
treatment and care through research activities which are
not available otherwise in a resource constrained setting
raise an ethical dilemma, particularly if an investigational
new drug is being evaluated, which was not the case here
where the treatment was in line with the national standard
of care.
Poor understanding of trial specific procedures was
also reported despite participants’ satisfaction with treat-
ment and nursing care. Similar findings have been ob-
served in other developing and non-developing country
settings [6,16]. In India, a study assessing comprehension
of informed consent concluded that the comprehension
could be reasonably good providing the consent form was
explained in simple language to the participants [17]. A
recent article involving oncology patients at the University
of Wisconsin, Madison, found that one-fifth of sub-
jects had considerably less understanding of study aims,methods and risks [18]. It has increasingly been acknowl-
edged by the scientific community that the lengthy, com-
plicated informed consent process needs to be adapted
and a shorter, more understandable consent form will bet-
ter enable participants to understand the implications of
their research participation, benefits, risks and obligations;
to have clear, complete information while making a
decision. The informed consent process is in danger
of becoming a box-ticking exercise focused more on
offering legal protection to a trial’s sponsor and illustrating
GCP compliance rather than its original intention of pro-
tecting participants and ensuring comprehension of study
information [19].
Limitations of this research study are the small sample
size and the lack of characterization of those patients
who refused to participate. However some clear themes
did emerge even with this number of subjects. This
study was not designed to measure consent comprehen-
sion directly but rather aimed at gathering evidence on
subjects’ understanding and perceptions of research.
Consent comprehension is a complex issue. Bloom’s
Taxonomy of Educational Objectives emphasized six
levels of cognitive skills related to informed consent:
knowledge, comprehension, application, analysis, synthe-
sis, and evaluation [20]. Understanding is a complex
process containing cognitive, logical and emotional com-
ponents. Understanding requires memory but memory
does not require understanding. Memory capacity and
overload are a concern in a trial like this. Consent forms
usually include at least eight ‘required elements’ and six
‘when appropriate’ elements. Memory research shows
that people can hold about 3–5 items in their working
memory [21]. It is unrealistic to expect subjects to re-
member much from a prolonged consent discussion
with an information sheet stretching to several pages,
especially when they are unwell. Another important
issue is readability, even more complex in a developing
country where many of the potential participants are
illiterate. The regulatory authorities and Institutional
review boards (IRBs) recommend that consent forms
should be written at a sixth-eighth grade reading
level. Readability alone does not ensure understand-
ing. Comprehension will be lower if consent forms
contain many words that are familiar to researchers
but unfamiliar to subjects. Subjects’ reading skills,
existing knowledge of clinical trials, their interest or
disinterest in reading the complete form are important
considerations.
There are inconsistent research findings in the literature
on the effectiveness of strategies designed to improve
understanding and consent comprehension [22]. Several
intervention strategies and tools, such as multimedia
technology (video and computer interventions), enhanced
or modified consent forms (shortened form, improved
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an additional person-to-person interaction after the initial
formal standard consent process have been assessed and
showed a range of effectiveness in specific research con-
texts [23]. It was concluded that longer contact between a
researcher or a nurse or a neutral counselor and a pro-
spective subject was the only method which appeared to
produce consistent comprehension improvements. Malaria
patients usually have fever and are unwell when they are
recruited to a clinical study and it may be that a second
discussion 24–48 hours after enrolment to explain the
aims of the study again and the meaning of their consent
would result in improved comprehension. It is also note-
worthy that none of these participants had any prior
experience of research. The rates of patient refusal to
participate to the clinical trial itself were several-fold higher
at other sites where patients were research-experienced
(E Ashley personal communication 2014).Conclusions
This small-scale study described the baseline under-
standing of subjects enrolled in a malaria research trial
in Bangladesh. The findings indicate a need to improve
the informed consent process in regards to information
provision and study comprehension. A second discus-
sion when patients have recovered from their presenting
symptoms of acute malaria might lead to improved com-
prehension and more informed consent. In many resource
constrained settings, research participation offers impro-
ved access to quality health care services and free treat-
ment which are either not available or perceived to be
unavailable in routine medical care, meaning potential
participants are more vulnerable and less likely to refuse
to take part. Another way to improve the safeguarding of
patients’ interests may be to engage the community prior
to the research [24-26]. This study was an initial attempt
to have a better understanding of research participants’
perceptions and understanding of research and to deter-
mine factors influencing their decision making process.
The findings suggest that use of a standard consent form
following the current ICH-GCP guidelines does not result
in achieving fully informed consent and the process
should be revised, simplified and adapted to individual
trial settings.Additional files
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